Functional polymorphisms in the promoter of the IL6 gene and in the promoter region of the serotonin transporter (5-HTT) gene [111] have been shown to be associated with a lower risk of symptoms of depression during IFNα treatment. This evidence concerns the gene IFNA2 and depressive symptom measurement.